Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Rivaroxaban 5 mg
DRUG
2 trials
Sponsors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
, Second Xiangya Hospital of Central South University
Conditions
Acute Coronary Syndrome
Myocardial Infarction
Myocardial Ischemia
Unstable Angina
Phase 3
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
Completed
NCT00809965
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia +1
Start: 2008-11-30
End: 2011-09-30
Updated: 2014-09-17
Phase 4
Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
Completed
NCT03363035
Second Xiangya Hospital of Central South University
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia +1
Start: 2018-01-15
End: 2021-11-30
Updated: 2022-02-22
Related Papers
U-shaped association between plasma cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) levels and myocardial infarction.
2025-02-19
Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial
Frontiers in Cardiovascular Medicine
2024-01-08
10 citations
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome
JAMA Network Open
2023-02-10
9 citations
Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE.
2020-09-23
1 citations
Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis.
2020-01-01
35 citations
Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.
2018-07-01
9 citations
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
2013-04-16
64 citations
Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
2013-03-07
58 citations
Rivaroxaban in patients with a recent acute coronary syndrome.
2011-11-13
1248 citations
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
2011-05-01
59 citations